Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model

References

• Andersohn F, Suissa S, Garbe E. 2006. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation. 113:1950–1957.
   PubMed Web of Science ®Google Scholar
• Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, Leeson P, Neubauer S, Ratnatunga C, Pillai R, et al. 2006. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation. 114:1193–1201.
   PubMed Web of Science ®Google Scholar
• Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, et al. 2006. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 355:885–895.
   PubMed Web of Science ®Google Scholar
• Ashkavand Z, Malekinejad H, Amniattalab A, Rezaei-Golmisheh A, Vishwanath BS. 2012. Silymarin potentiates the anti-inflammatory effects of celecoxib on chemically induced osteoarthritis in rats. Phytomedicine. 19:1200–1205.
   PubMed Web of Science ®Google Scholar
• Bazzano LA, Reynolds K, Holder KN, He J. 2006. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA. 296:2720–2726.
   PubMed Web of Science ®Google Scholar
• Bergmeyer HU, editor. 1974. Lactate dehydrogenase. In: Methods of enzymatic analysis. 2nd English ed. (Translated from the Third German Edition), Williamson DH, ed. New York: Academic Press; p. 574–579.
   Google Scholar
• Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. 2003. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs. 63:525–534.
   PubMed Web of Science ®Google Scholar
• Bolli R, Shinmura K, Tang XL, Kodani E, Xuan YT, Guo Y, Dawn B. 2002. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischaemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res. 55:506–519.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al. 2000. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 343:1520–1528.
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, et al. 2005. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 352:1092–1102.
   PubMed Web of Science ®Google Scholar
• Brueggemann LI, Mackie AR, Mani BK, Cribbs LL, Byron KL. 2009. Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol Pharmacol. 76:1053–1061.
   PubMed Web of Science ®Google Scholar
• Buchineni M, Kumar MR, Kudagi BL, Pathapati RM, Salmakamal Haritha M, Chandra VB. 2014. Evaluation of anti-inflammatory and analgesic activity of Azadirachta indica (leaf) extract in chemical and thermal induced pain models in rats. Int J Toxicol Pharmacol Res. 6:144–147.
   Google Scholar
• Chatterjee K, Zhang J, Honbo N, Karliner JS. 2010. Doxorubicin cardiomyopathy. Cardiology. 115:155–162.
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Oates JC, McCune WJ, Gupta S, Kaplan MJ, Catella-Lawson F, Morrow JD, McDonagh KT, Schmaier AH. 2000. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum. 43:1891–1896.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. 2005. Public Health Advisory-FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory Drugs (NSAIDs) [Internet]. [cited 2005 Jul 4]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.htm
   Google Scholar
• Förstermann U, Münzel T. 2006. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 113:1708–1714.
   PubMed Web of Science ®Google Scholar
• Frolov RV, Berim IG, Singh S. 2008. Inhibition of delayed rectifier potassium channels and induction of arrhythmia: a novel effect of celecoxib and the mechanism underlying it. J Biol Chem. 283:1518–1524.
   PubMed Web of Science ®Google Scholar
• Frolov RV, Ignatova II, Singh S. 2011. Inhibition of hERG potassium channels by celecoxib and its mechanism. PLoS One. 6:e26344.
   PubMed Web of Science ®Google Scholar
• Hagar HH. 2002. Folic acid and vitamin B12 supplementation attenuate isoprenaline-induced myocardial infarction in experimental hyperhomocysteinemic rats. Pharmacol Res. 46:213–219.
   PubMed Web of Science ®Google Scholar
• Herman EH, Lipshultz SE, Rifai N, Zhang J, Papoian T, Yu ZX, Takeda K, Ferrans VJ. 1998. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. 58:195–197.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. 2005. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 330:1366–1372.
   PubMed Web of Science ®Google Scholar
• Jia Y, Zuo D, Li Z, Liu H, Dai Z, Cai J, Pang L, Wu Y. 2014. Astragaloside IV inhibits doxorubicin-induced cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway via activating the PI3K/Akt pathway. Chem Pharm Bull. 62:45–53.
   PubMed Web of Science ®Google Scholar
• Li T, Danelisen I, Belló-Klein A, Singal PK. 2000. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res. 46:523–530.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265–275.
   PubMed Web of Science ®Google Scholar
• Luo X, Reichetzer B, Trines J, Benson LN, Lehotay DC. 1999. l-Carnitine attenuates doxorubicin-induced lipid peroxidation in rats. Free Radic Biol Med. 26:1158–1165.
   PubMed Web of Science ®Google Scholar
• Marcus AJ, Broekman MJ, Pinsky DJ. 2002. COX inhibitors and thromboregulation. N Engl J Med. 347:1025–1026.
   PubMed Web of Science ®Google Scholar
• McCarty MF. 2007. Oster rediscovered-mega-dose folate for symptomatic atherosclerosis. Med Hypotheses. 69:325–332.
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. 2006. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 296:1633–1644.
   PubMed Web of Science ®Google Scholar
• Miao Y, Zhang Y, Lim PS, Kanjanapan Y, Mori TA, Croft KD, Earl J, Lee SY, McKenzie KU, Hu L, et al. 2007. Folic acid prevents and partially reverses glucocorticoid-induced hypertension in the rat. Am J Hypertens. 20:304–310.
   PubMed Web of Science ®Google Scholar
• Moat SJ, Lang D, McDowell IF, Clarke ZL, Madhavan AK, Lewis MJ, Goodfellow J. 2004. Folate, homocysteine, endothelial function and cardiovascular disease. J Nutr Biochem. 15:64–79.
   PubMed Web of Science ®Google Scholar
• Moat SJ, Madhavan A, Taylor SY, Payne N, Allen RH, Stabler SP, Goodfellow J, McDowell IF, Lewis MJ, Lang D. 2006. High‐but not low‐dose folic acid improves endothelial function in coronary artery disease. Eur J Clin Invest. 36:850–859.
   PubMed Web of Science ®Google Scholar
• Moens A. 2009. Protective effect of high dose folate on myocardial ischaemia. US patent application 12/735,550.
   Google Scholar
• Moens AL, Champion HC, Claeys MJ, Tavazzi B, Kaminski PM, Wolin MS, Borgonjon DJ, Van Nassauw L, Haile A, Zviman M, et al. 2008. High-dose folic acid pretreatment blunts cardiac dysfunction during ischaemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation. 117:1810–1819.
   PubMed Web of Science ®Google Scholar
• Moens AL, Claeys MJ, Wuyts FL, Goovaerts I, Van Hertbruggen E, Wendelen LC, Van Hoof VO, Vrints CJ. 2007. Effect of folic acid on endothelial function following acute myocardial infarction. Am J Cardiol. 99:476–481.
   PubMed Web of Science ®Google Scholar
• Mohamed HE, Asker ME, Ali SI, el-Fattah TM. 2004. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. J Pharm Pharmacol. 56:757–768.
   PubMed Web of Science ®Google Scholar
• Molina R, Sánchez M, Hidalgo A, Garcia de Boto MJ. 1994. Influences of age and sex on endothelium-dependent vascular responses and arterial blood pressure in the rat. Gen Pharmacol. 25:753–759.
   PubMedGoogle Scholar
• Mukherjee D, Topol EJ. 2003. Cox-2: where are we in 2003? – Cardiovascular risk and Cox-2 inhibitors. Arthritis Res Ther. 5:8–11.
   PubMed Web of Science ®Google Scholar
• Muscará MN, Vergnolle N, Lovren F, Triggle CR, Elliott SN, Asfaha S, Wallace JL. 2000. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol. 129:1423–1430.
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. 2005. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 352:1081–1091.
   PubMed Web of Science ®Google Scholar
• Ohkawa H, Ohishi N, Yagi K. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 95:351–358.
   PubMed Web of Science ®Google Scholar
• Pandey R, Gupta S, Lal H, Mehta HC, Aggarwal SK. 2000. Hyperhomocysteinemia and cardiovascular disease: the nutritional perspectives. Indian J Clin Biochem. 15:20–30.
   PubMedGoogle Scholar
• Pontes JC, Gomes Júnior JF, Silva GV, Benfatti RA, Dias AE, Duarte JJ, Gardenal N, Odashiro M, Santos CH. 2010. Anatomopathological study of cardiomyopathy induced by doxorubicin in rats. Acta Cir Bras. 25:137–143.
   PubMed Web of Science ®Google Scholar
• Reagan-Shaw S, Nihal M, Ahmad N. 2007. Dose translation from animal to human studies revisited. FASEB J 22:659–661.
   PubMed Web of Science ®Google Scholar
• Rios A, Vargas-Robles H, Gámez-Méndez AM, Escalante B. 2012. Cyclooxygenase-2 and kidney failure. Prostaglandins Other Lipid Mediat. 98:86–90.
   PubMed Web of Science ®Google Scholar
• Rosalki SB. 1967. An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med. 69:696–705.
   PubMed Web of Science ®Google Scholar
• Sedlak J, Lindsay RH. 1968. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem. 25:192–205.
   PubMed Web of Science ®Google Scholar
• Segev G, Katz RJ. 2004. Selective COX-2 inhibitors and risk of cardiovascular events. Hosp Phys. 40:39–46.
   Google Scholar
• Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A, Bolli R. 2000. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA. 97:10197–10202.
   PubMed Web of Science ®Google Scholar
• Shirodaria C, Antoniades C, Lee J, Jackson CE, Robson MD, Francis JM, Moat SJ, Ratnatunga C, Pillai R, Refsum H, et al. 2007. Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease. Circulation. 115:2262–2270.
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al. 2000. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 284:1247–1255.
   PubMed Web of Science ®Google Scholar
• Siveski-Iliskovic N, Kaul N, Singal PK. 1994. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation. 89:2829–2835.
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. 2005. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 352:1071–1080.
   PubMed Web of Science ®Google Scholar
• Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG. 2005. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 165:161–168.
   PubMed Web of Science ®Google Scholar
• Tawakol A, Migrino RQ, Aziz KS, Waitkowska J, Holmvang G, Alpert NM, Muller JE, Fischman AJ, Gewirtz H. 2005. High-dose folic acid acutely improves coronary vasodilator function in patients with coronary artery disease. J Am Coll Cardiol. 45:1580–1584.
   PubMed Web of Science ®Google Scholar
• Whelton A, Maurath CJ, Verburg KM, Geis GS. 2000. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther. 7:159–175.
   PubMedGoogle Scholar
• Wu TG, Li WH, Lin ZQ, Wang LX. 2008. Effects of folic acid on cardiac myocyte apoptosis in rats with streptozotocin-induced diabetes mellitus. Cardiovasc Drugs Ther. 22:299–304.
   PubMed Web of Science ®Google Scholar